Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

Regulators to improve cooperation on generic drugs

EMA to spearhead information sharing initiative

- PMLiVE

Amgen and Kite in $1bn cancer immunotherapy tie up

Latest major research deal in growing area of oncology

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

EMA picks projects for adaptive licensing project

Begins discussions on how the model will be implemented in practice

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

- PMLiVE

‘Major step forward’ as EMA recommends first stem cell therapy

But wants more clinical trial data to shore up orphan drug's marketing licence

- PMLiVE

Amgen sets premium price for Blincyto

Leukaemia drug becomes one of the most expensive pharma products on the market

- PMLiVE

Data transparency in Europe

Will 2015 usher in a new era?

- PMLiVE

EMA: Lack of evidence for Ebola treatments

Not enough data to draw conclusions on effectiveness of experimental drugs

EU flag

EC: Search for Rasi’s replacement could take six months

Commission tells PMLiVE process could still be impacted by the procedure's complexity

- PMLiVE

Amgen’s Xgeva cleared in US for rare bone cancer complication

Hypercalcaemia of malignancy affects around 2.7% of cancer patients

- PMLiVE

New ASPIRE data boosts Amgen’s Kyprolis

Trial results presented at ASH show drug can be safely added to standard chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links